Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Anti-PD-1-Resistant Locally Advanced or Metastatic Cancers

Next Previous
Search
Trial Profile

A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Anti-PD-1-Resistant Locally Advanced or Metastatic Cancers

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alintegmod (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Colorectal cancer; Liver cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors 7 Hills Pharma

    • Most Recent Events

    • 03 Sep 2024 According to a 7 Hills Pharma media release, this study is supported by a $13.4 million award from the Cancer Prevention and Research Institute of Texas (DP230062) and a $2.0 million award from the National Cancer Institute (R44CA285207).
    • 03 Sep 2024 According to a 7 Hills Pharma media release, first cancer patient has been safely dosed with alintegimod in this study.
    • 29 Jul 2024 Planned initiation date changed from 30 Apr 2024 to 1 Aug 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top